The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications

Amir Hossein Miri; Mojtaba Kamankesh; Antoni Llopis-Lorente; Chenguang Liu; Matthias G. Wacker; Ismaeil Haririan; Hamid Asadzadeh Aghdaei; Michael R. Hamblin; Abbas Yadegar; Mazda Rad-Malekshahi; Mohammad Reza Zali

doi:10.3389/fphar.2022.917184

The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications

Amir Hossein Miri
, Mojtaba Kamankesh
, Antoni Llopis-Lorente
, Chenguang Liu
, Matthias G. Wacker
, Ismaeil Haririan
, Hamid Asadzadeh Aghdaei
, Michael R. Hamblin
, Abbas Yadegar
, Mazda Rad-Malekshahi
, Mohammad Reza Zali

Laser Research Centre

Tehran University of Medical Sciences
Shahid Beheshti University of Medical Sciences
University of Tehran
Eindhoven University of Technology
Ocean University of China
National University of Singapore

Research output: Contribution to journal › Review article › peer-review

13 Citations (Scopus)

Abstract

Helicobacter pylori (H. pylori) is a notorious, recalcitrant and silent germ, which can cause a variety of debilitating stomach diseases, including gastric and duodenal ulcers and gastric cancer. This microbe predominantly colonizes the mucosal layer of the human stomach and survives in the inhospitable gastric microenvironment, by adapting to this hostile milieu. In this review, we first discuss H. pylori colonization and invasion. Thereafter, we provide a survey of current curative options based on polypharmacy, looking at pharmacokinetics, pharmacodynamics and pharmaceutical microbiology concepts, in the battle against H. pylori infection.

Original language	English
Article number	917184
Journal	Frontiers in Pharmacology
Volume	13
DOIs	https://doi.org/10.3389/fphar.2022.917184
Publication status	Published - 27 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

H. pylori
antibiotic therapy
biopharmaceutical principles
pharmaceutical microbiology
pharmacodynamics
pharmacokinetics

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.3389/fphar.2022.917184

Cite this

Miri, A. H., Kamankesh, M., Llopis-Lorente, A., Liu, C., Wacker, M. G., Haririan, I., Asadzadeh Aghdaei, H., Hamblin, M. R., Yadegar, A., Rad-Malekshahi, M., & Zali, M. R. (2022). The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications. Frontiers in Pharmacology, 13, Article 917184. https://doi.org/10.3389/fphar.2022.917184

@article{4ee9b314618142ee9ced43432b2f6d8a,

title = "The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications",

abstract = "Helicobacter pylori (H. pylori) is a notorious, recalcitrant and silent germ, which can cause a variety of debilitating stomach diseases, including gastric and duodenal ulcers and gastric cancer. This microbe predominantly colonizes the mucosal layer of the human stomach and survives in the inhospitable gastric microenvironment, by adapting to this hostile milieu. In this review, we first discuss H. pylori colonization and invasion. Thereafter, we provide a survey of current curative options based on polypharmacy, looking at pharmacokinetics, pharmacodynamics and pharmaceutical microbiology concepts, in the battle against H. pylori infection.",

keywords = "H. pylori, antibiotic therapy, biopharmaceutical principles, pharmaceutical microbiology, pharmacodynamics, pharmacokinetics",

author = "Miri, \{Amir Hossein\} and Mojtaba Kamankesh and Antoni Llopis-Lorente and Chenguang Liu and Wacker, \{Matthias G.\} and Ismaeil Haririan and \{Asadzadeh Aghdaei\}, Hamid and Hamblin, \{Michael R.\} and Abbas Yadegar and Mazda Rad-Malekshahi and Zali, \{Mohammad Reza\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Miri, Kamankesh, Llopis-Lorente, Liu, Wacker, Haririan, Asadzadeh Aghdaei, Hamblin, Yadegar, Rad-Malekshahi and Zali.",

year = "2022",

month = jun,

day = "27",

doi = "10.3389/fphar.2022.917184",

language = "English",

volume = "13",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - The Potential Use of Antibiotics Against Helicobacter pylori Infection

T2 - Biopharmaceutical Implications

AU - Miri, Amir Hossein

AU - Kamankesh, Mojtaba

AU - Llopis-Lorente, Antoni

AU - Liu, Chenguang

AU - Wacker, Matthias G.

AU - Haririan, Ismaeil

AU - Asadzadeh Aghdaei, Hamid

AU - Hamblin, Michael R.

AU - Yadegar, Abbas

AU - Rad-Malekshahi, Mazda

AU - Zali, Mohammad Reza

PY - 2022/6/27

Y1 - 2022/6/27

N2 - Helicobacter pylori (H. pylori) is a notorious, recalcitrant and silent germ, which can cause a variety of debilitating stomach diseases, including gastric and duodenal ulcers and gastric cancer. This microbe predominantly colonizes the mucosal layer of the human stomach and survives in the inhospitable gastric microenvironment, by adapting to this hostile milieu. In this review, we first discuss H. pylori colonization and invasion. Thereafter, we provide a survey of current curative options based on polypharmacy, looking at pharmacokinetics, pharmacodynamics and pharmaceutical microbiology concepts, in the battle against H. pylori infection.

AB - Helicobacter pylori (H. pylori) is a notorious, recalcitrant and silent germ, which can cause a variety of debilitating stomach diseases, including gastric and duodenal ulcers and gastric cancer. This microbe predominantly colonizes the mucosal layer of the human stomach and survives in the inhospitable gastric microenvironment, by adapting to this hostile milieu. In this review, we first discuss H. pylori colonization and invasion. Thereafter, we provide a survey of current curative options based on polypharmacy, looking at pharmacokinetics, pharmacodynamics and pharmaceutical microbiology concepts, in the battle against H. pylori infection.

KW - H. pylori

KW - antibiotic therapy

KW - biopharmaceutical principles

KW - pharmaceutical microbiology

KW - pharmacodynamics

KW - pharmacokinetics

UR - https://www.scopus.com/pages/publications/85133941672

U2 - 10.3389/fphar.2022.917184

DO - 10.3389/fphar.2022.917184

M3 - Review article

AN - SCOPUS:85133941672

SN - 1663-9812

VL - 13

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 917184

ER -

The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this